Hypertrophic Cardiomyopathy Research

The OHSU Hypertrophic Cardiomyopathy Center leads an active research program spanning genetics, molecular pathways, translational research, therapeutics and clinical trials. Our experienced research team have been leading the majority of clinical trials shaping the future of HCM.

If you would like to participate in a clinical trial or schedule an appointment please call 503-494-1775.

If you have questions pertaining to ongoing or future clinical trials and research at the OHSU HCM Center, please email Dr. Ahmad Masri at masria@ohsu.edu

  • HCM-Bank: The OHSU Hypertrophic Cardiomyopathy BioBank
  • REDWOOD-HCM: Randomized Evaluation of Dosing With CK-3773274 in Obstructive Outflow Disease in HCM (clinicaltrials.gov identifier: NCT04219826)
  • VALOR-HCM: A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy (clinicaltrials.gov identifier: NCT04349072)

  • Novel Markers of Prognosis in Hypertrophic Cardiomyopathy (HCMR)
  • The goal of the Lifestyle and Exercise in Hypertrophic Cardiomyopathy Study (LIVE-HCM)
  • An Open-label Extension Study of Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER-OLE)
  • A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials
  • The OHSU Hypertrophic Cardiomyopathy Registry

  • A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacamten (MYK-461) in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction (MAVERICK-HCM)
  • A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (Pioneer-HCM)
  • A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER)
  • A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (GS-US-361-1157)
  • A Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients with Hypertrophic Cardiomyopathy and Moderate-to Severe Heart Failure with Preserved Left Ventricular Function
  • Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM)